Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2011

Affymetrix to Pay $330M to acquire eBioscience

  • Affymetrix is buying San Diego-based eBioscience for $330 million in cash. eBioscience is specialized in the field of flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

    Affymetrix says the acquisition will complement its traditional businesses of genomics and cytogenetics, enhance its molecular diagnostics business, and expand its product portfolio to include multicolor flow cytometry reagents and a range of reagents for analyzing cytokines, growth factors, and other soluble proteins. The takeover will in addition boost new product and growth opportunities for its Panomics subsidiary’s RNA and protein analysis business.

    eBiosciences is predicted to generate sales of over $70 million in 2011, with gross margins in excess of 70%, Affymetrix says. “The acquisition of eBioscience is transformational for our business,” comments Frank Witney, Ph.D., president and CEO. “With eBioscience, Affymetrix will significantly expand its addressable markets by adding an industry-leading portfolio of cell-based assays and immunoassays. These new products are a critical part of our customers’ workflow in our key target markets of translational medicine, oncology, and immunology.”  

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »